 |
AcelRx is
an early stage company developing a novel drug delivery platform
technology.
 |
575 Chesapeake Drive
Redwood City, CA 94063
Phone:650.216.3500
Fax: 650.216.6500 |
 |
 |
Advion is leading manufacturer of microfluidics systems for chemistry and biochemistry applications, and operates the scientific leader in LC/MS and immunoassay services.
|
19 Brown Road
Ithaca, NY 14850 USA
Phone:
607.266.0665
Fax:
607.266.0749 |
|
 |
Applied Genetic
Technologies Corporation (AGTC) is developing gene therapy products
derived from adeno-associated virus (AAV) for the treatment of inherited
and acquired diseases.
|
11801 Research Drive, Suite D
Alachua, Florida 32615
Phone:
386.462.2204
Fax:
386.462.7396 |
|
 |
ARCA Discovery is developing a third generation beta-blocker and vasodilator for advanced heart failure which promises to be the first drug that analyzes the patient’s own genetics to customize therapy. The Company plans to submit a New Drug Application in 2008. ARCA Discovery recently submitted a New Drug Application for a fourth generation beta-blocker and vasodilator for advanced heart failure which promises to be the first drug that analyzes the patient’s own genetics to customize therapy.
|
8001 Arista Place, Suite 200
Broomfield, CO 80021
Phone:720.940.2200
Fax: 720.208.9261 |
|
 |
Avidia is focused on discovering and developing a new class of human therapeutic proteins called Avimers™ which are derived from a family of small, naturally-occurring protein binding domains. The company was acquired by Amgen [NASDAQ: AMGN] in September of 2006. |
2450 Bayshore Parkway
Suite 200
Mountain View CA 94043
Phone:
650.404.2000
Fax:
650.404.2001 |
|
Logo coming soon. |
Calibra Medical, Inc. makes a tiny, wearable, all-mechanical insulin delivery device containing a 3-day supply of insulin that can be actuated through clothing, allowing simple, discreet insulin administration without the need for complicated, programmable pumps.
Website coming soon. |
220 Saginaw Drive
Redwood City, CA 94063 |
|
 |
Concert Pharmaceuticals was founded to utilize deuterium substitution to improve existing drugs.
|
99 Hayden Avenue, Suite 500
Lexington, MA 02421
Phone: 781.860.0045
Fax: 781.860.8923 |
|
 |
Dicerna Pharmaceuticals is developing novel therapeutics in multiple therapeutic areas based on Dicer substrate technology, which makes use of the RNA interference mechanism. Dicerna’s intellectual property covers double stranded RNA molecules 26-30 base pairs in length, which are generally more potent in inducing RNA interference than the conventional 19-23 base pair sequences.
|
790 Memorial Drive, Suite 104
Cambridge, MA 02139
Phone: 617.621.8097 |
|
 |
Proprietary assays
for high throughput screening and other applications in drug discovery.
|
42501 Albrae Street
Fremont, CA 94538
Phone:
866.448.4864
Fax:
510.979.1650 |
|
 |
Dow is a leading
contract formulator of prescription drugs for dermatology applications.
In the past several years, Dow has been reinvesting its profits
into developing new drug formulations for its own account, taking
them into Phase II clinical trials before licensing them to a partner.
|
1330A Redwood Way
Petaluma, CA 94954-1169
Phone:
707.793.2600
Fax: 707.793.0145 |
|
 |
Ultra compact cell
analysis systems and reagents that require less operator training
than conventional flow cytometry systems.
|
25801 Industrial Boulevard
Hayward, CA 94545-2991
Phone:
866.448.2827
Fax: 510.576.1500 |
|
 |
Hansen Medical introduces
the power of instinctive catheter movement. This revolutionary technology
is designed to deliver precise three-dimensional catheter control
to complex interventional procedures.
|
[NASDAQ: HNSN] |
|
800 East Middlefield Road
Mountain View, CA 94043
Phone:650.404.5800
Fax: 650.404.5901 |
|
 |
The company seeks to correct knee malalignment through an instrumented system to guide a reproducible and precise surgical technique called high tibial osteotomy.
|
4900 Nautilus Ct, Suite 100
Boulder, CO 80503
Phone:
303.381.6333 |
|
 |
InteKrin is developing an insulin sensitizing drug called INT131, which is in Phase 2b development for treatment of Type II diabetes. As a new chemical class that affects its target in a novel way, INT131 was designed to avoid the characteristic adverse effects of other insulin sensitizers, such as weight gain or edema. In animal studies and Phase 2a trials, the drug showed strong efficacy without these adverse effects.
|
4300 El Camino Real, Suite 201
Los Altos, CA 94022
Phone: 650.941.5501
Fax: 866.286.2242 |
|
 |
Therapeutics that
specifically inhibit or enhance individual isoforms of Protein Kinase
C (PKC).
|
270 Littlefield Road
South San Francisco, CA 94080-6924
Phone:
650.244.1100 |
|
 |
Improved administration
of inhaled drugs, including a version of budesonide, the leading
nebulized steroid for small children. MAP’s version of budesonide
promises to decrease administration time significantly, allowing
MAP’s version to potentially become the standard budesonide
therapy for these patients.
|
2400 Bayshore Parkway, Suite 200
Mountain View, CA 94043
Phone:
650.386.3100
Fax:
650.386.3101 |
|
 |
Medivance is the leading company in therapeutic hypothermia. It is the only company to produce a practical solution that uses consumables and equipment for the non-invasive production of therapeutic hypothermia.
|
1172 Century Drive, Suite 240
Louisville, CO 80027
Phone:
303.926.1917
Fax: 303.926.1924 |
|
 |
High-density, fully-custom microarrays for any sequences of any genome, up to 60-mers in length. The company was purchased by Roche Holdings [RO.SW] in 2007.
|
500 South Rosa Road
Madison, WI 53719
Phone:
608.218.7600
Fax:
608.218.7601 |
|
 |
NovaCardia is a product-focused pharmaceutical company developing and commercializing a portfolio of novel small molecule drugs with an initial focus on the acute cardiac care marketplace. The company was acquired by Merck & Co. [NYSE: MRK] in September of 2007. |
12651 High Bluff Drive
Suite 200
San Diego, CA 92130
Phone:858.509.0455
Fax:858.509.0456 |
|
 |
Novasys Medical's first product, the Renessa® System, is a proprietary, FDA-approved, non-surgical treatment for female stress urinary incontinence (SUI), a disorder that affects over 15 million women in the United States. The Renessa System uses radiofrequency energy to remodel the patient’s own collagen in the bladder and urethra, firming the tissue and reducing incontinence episodes. The treatment offers women and their physicians a new, non-incisional treatment option for SUI. It is performed painlessly in a doctor’s office under local anesthesia, in less than an hour.
|
39684 Eureka Drive
Newark, CA 94560
Phone:510.226.4060
Fax:510.353.0524 |
|
 |
Proteon Therapeutics’
Type I Elastase permanently dilates blood vessels. It is being developed
to enlarge potential hemodialysis access sites in renal failure
patients, increasing the number of possible access sites and prolonging
the life of new access sites.
|
4420 Madison Avenue
Suite 180
Kansas City, MO 64111
Phone:
816.531.0028
Fax:
816.531.3079 |
|
 |
Satiety has developed a minimally invasive approach to weight loss surgery, with impressive results in its initial human trials.
|
2470 Embarcadero Way
Palo Alto, CA 94303
Phone: 650.320.2100
Fax: 650.320.2150 |
|
 |
Sequel Pharmaceuticals is developing a novel drug targeting several ion channels for the treatment and prevention of atrial fibrillation.
|
12750 High Bluff Drive, Suite 300
San Diego, CA 92130
Phone: 858.509.0455
Fax: 858.509.0456 |
|
 |
Sirtris is focused on discovering and developing proprietary, orally available drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Its drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins, a recently discovered class of enzymes that control the aging process. The company was acquired by GlaxoSmithKline for $720 million in June 2008.
|
[NASDAQ: SIRT] |
|
790 Memorial Drive
Cambridge, MA 02139
Phone: 617.252.6920
Fax: 617.252.6924 |
|
 |
Spinal Motion is in late
stage US clinical trials of its artificial discs for treating patients
with degenerative disc disease in the lumbar and cervical spine.
Its products were invented in South Africa and are on the market
there with excellent results.
|
201 San Antonio Circle
Suite 115, Building B
Mountain View, CA 94040
Phone: 650.947.3472
Fax: 650.947.3473 |
|
 |
Targanta
has successfully completed two Phase 3 trials for oritavancin, a
drug for serious gram-positive hospital-acquired infections, including
those that are that are resistant to other drugs. Oritavancin appears
to have the broadest spectrum and highest potency in its class,
and because of its mechanism of action, gram-positive bacteria are
less likely to develop resistance to oritavancin than to other antibiotics. Targanta has recently submitted a New Drug Application for oritavancin, a drug for serious gram-positive hospital-based infections, including those that are that are resistant to other drugs.
|
222 3rd St.
Suite 2300
Cambridge, MA 02142
Phone: 617.577.9020
Fax: 617.577.9021 |
|
 |
Tetraphase Pharmaceuticals, Inc is attempting to discover and develop novel tetracycline-based antibiotic drugs. The company is based on the first complete synthesis of the tetracycline scaffold, which allows medicinal chemists to synthesize tetracycline derivatives that previously were impossible to create.
|
480 Arsenal Street, Ste 110
Watertown, MA 02472
Phone: 617.715.3600
Fax: 617.926.3557 |
|
 |
Tolerx is focused on the discovery, development, and commercialization of novel immunotherapies designed to reprogram the immune system and provide a long-term, durable remission after a short course of therapy. Its leading drug is a monoclonal that promises to allow newly-diagnosed Type I diabetes patients to preserve their ability to produce endogenous insulin.
|
300 Technology Square
3th Floor
Cambridge, MA 02139
Phone:
617.354.8100
Fax: 617.354.8300 |
|
 |
The leading company in Engineered Drug Transport(tm), which uses active transport systems to improve the oral absorption, distribution, and pharmacokinetics of existing active drug ingredients. Its lead drug has completed three positive Phase 3 clinical trials, and a second drug has completed a positive Phase 2a clinical trial, and a third drug has completed a positive Phase 1 clinical trial.
|
[NASDAQ: XNPT] |
|
3410 Central Expressway
Santa Clara, CA 95051
Phone: 408.616.7200
Fax: 408.616.7210 |
About Us